477 related articles for article (PubMed ID: 32162152)
1. Drug retention of secondary biologics or JAK inhibitors after tocilizumab or abatacept failure as first biologics in patients with rheumatoid arthritis -the ANSWER cohort study.
Ebina K; Hirano T; Maeda Y; Yamamoto W; Hashimoto M; Murata K; Takeuchi T; Nagai K; Son Y; Amuro H; Onishi A; Jinno S; Hara R; Katayama M; Yamamoto K; Kumanogoh A; Hirao M
Clin Rheumatol; 2020 Sep; 39(9):2563-2572. PubMed ID: 32162152
[TBL] [Abstract][Full Text] [Related]
2. Drug retention of 7 biologics and tofacitinib in biologics-naïve and biologics-switched patients with rheumatoid arthritis: the ANSWER cohort study.
Ebina K; Hirano T; Maeda Y; Yamamoto W; Hashimoto M; Murata K; Takeuchi T; Shiba H; Son Y; Amuro H; Onishi A; Akashi K; Hara R; Katayama M; Yamamoto K; Kumanogoh A; Hirao M
Arthritis Res Ther; 2020 Jun; 22(1):142. PubMed ID: 32539813
[TBL] [Abstract][Full Text] [Related]
3. Drug tolerability and reasons for discontinuation of seven biologics in 4466 treatment courses of rheumatoid arthritis-the ANSWER cohort study.
Ebina K; Hashimoto M; Yamamoto W; Hirano T; Hara R; Katayama M; Onishi A; Nagai K; Son Y; Amuro H; Yamamoto K; Maeda Y; Murata K; Jinno S; Takeuchi T; Hirao M; Kumanogoh A; Yoshikawa H
Arthritis Res Ther; 2019 Apr; 21(1):91. PubMed ID: 30971306
[TBL] [Abstract][Full Text] [Related]
4. Drug tolerability and reasons for discontinuation of seven biologics in elderly patients with rheumatoid arthritis -The ANSWER cohort study.
Ebina K; Hashimoto M; Yamamoto W; Hirano T; Hara R; Katayama M; Onishi A; Nagai K; Son Y; Amuro H; Yamamoto K; Maeda Y; Murata K; Jinno S; Takeuchi T; Hirao M; Kumanogoh A; Yoshikawa H
PLoS One; 2019; 14(5):e0216624. PubMed ID: 31067271
[TBL] [Abstract][Full Text] [Related]
5. Drug retention and discontinuation reasons between seven biologics in patients with rheumatoid arthritis -The ANSWER cohort study.
Ebina K; Hashimoto M; Yamamoto W; Ohnishi A; Kabata D; Hirano T; Hara R; Katayama M; Yoshida S; Nagai K; Son Y; Amuro H; Akashi K; Fujimura T; Hirao M; Yamamoto K; Shintani A; Kumanogoh A; Yoshikawa H
PLoS One; 2018; 13(3):e0194130. PubMed ID: 29543846
[TBL] [Abstract][Full Text] [Related]
6. Comparison of the clinical effectiveness of tumour necrosis factor inhibitors and abatacept after insufficient response to tocilizumab in patients with rheumatoid arthritis.
Akiyama M; Kaneko Y; Kondo H; Takeuchi T
Clin Rheumatol; 2016 Nov; 35(11):2829-2834. PubMed ID: 26971256
[TBL] [Abstract][Full Text] [Related]
7. Use and effectiveness of tocilizumab among patients with rheumatoid arthritis: an observational study from the British Society for Rheumatology Biologics Register for rheumatoid arthritis.
Kihara M; Davies R; Kearsley-Fleet L; Watson KD; Lunt M; Symmons DP; Hyrich KL;
Clin Rheumatol; 2017 Feb; 36(2):241-250. PubMed ID: 27913894
[TBL] [Abstract][Full Text] [Related]
8. Tocilizumab and rituximab have similar effectiveness and are both superior to a second tumour necrosis factor inhibitor in rheumatoid arthritis patients who discontinued a first TNF inhibitor.
Santos-Faria D; Tavares-Costa J; Eusébio M; Leite Silva J; Ramos Rodrigues J; Sousa-Neves J; Duarte AC; Lopes C; Valido A; Dinis J; Freitas J; Santiago M; Ferreira R; Ganhão S; Miranda L; Peixoto D; Teixeira F; Alcino S; Afonso C; Santos MJ
Acta Reumatol Port; 2019; 44(2):103-113. PubMed ID: 31243259
[TBL] [Abstract][Full Text] [Related]
9. Comparative effectiveness of antitumour necrosis factor agents, biologics with an alternative mode of action and tofacitinib in an observational cohort of patients with rheumatoid arthritis in Switzerland.
Finckh A; Tellenbach C; Herzog L; Scherer A; Moeller B; Ciurea A; von Muehlenen I; Gabay C; Kyburz D; Brulhart L; Müller R; Hasler P; Zufferey P;
RMD Open; 2020 May; 6(1):. PubMed ID: 32385143
[TBL] [Abstract][Full Text] [Related]
10. Comparing the effectiveness and safety of Abatacept and Tocilizumab in elderly patients with rheumatoid arthritis.
Temmoku J; Miyata M; Suzuki E; Sumichika Y; Saito K; Yoshida S; Matsumoto H; Fujita Y; Matsuoka N; Asano T; Sato S; Watanabe H; Migita K
PLoS One; 2022; 17(9):e0274775. PubMed ID: 36121851
[TBL] [Abstract][Full Text] [Related]
11. Comparative effectiveness of TNF inhibitors and tocilizumab with and without conventional synthetic disease-modifying antirheumatic drugs in a pan-European observational cohort of bio-naïve patients with rheumatoid arthritis.
Lauper K; Mongin D; Iannone F; Kristianslund EK; Kvien TK; Nordström DC; Pavelka K; Pombo-Suarez M; Rotar Z; Santos MJ; Codreanu C; Lukina G; Gale SL; John M; Luder Y; Courvoisier DS; Gabay C
Semin Arthritis Rheum; 2020 Feb; 50(1):17-24. PubMed ID: 31280937
[TBL] [Abstract][Full Text] [Related]
12. Differential long-term retention of biological disease-modifying antirheumatic drugs in patients with rheumatoid arthritis by age group from the FIRST registry.
Kawabe A; Nakano K; Kubo S; Asakawa T; Tanaka Y
Arthritis Res Ther; 2020 Jun; 22(1):136. PubMed ID: 32513309
[TBL] [Abstract][Full Text] [Related]
13. Risk of serious infections in tocilizumab versus other biologic drugs in patients with rheumatoid arthritis: a multidatabase cohort study.
Pawar A; Desai RJ; Solomon DH; Santiago Ortiz AJ; Gale S; Bao M; Sarsour K; Schneeweiss S; Kim SC
Ann Rheum Dis; 2019 Apr; 78(4):456-464. PubMed ID: 30679153
[TBL] [Abstract][Full Text] [Related]
14. Drug retention of biologics and Janus kinase inhibitors in patients with rheumatoid arthritis: the ANSWER cohort study.
Ebina K; Etani Y; Maeda Y; Okita Y; Hirao M; Yamamoto W; Hashimoto M; Murata K; Hara R; Nagai K; Hiramatsu Y; Son Y; Amuro H; Fujii T; Okano T; Ueda Y; Katayama M; Okano T; Tachibana S; Hayashi S; Kumanogoh A; Okada S; Nakata K
RMD Open; 2023 Aug; 9(3):. PubMed ID: 37597846
[TBL] [Abstract][Full Text] [Related]
15. Comparison of drug retention of TNF inhibitors, other biologics and JAK inhibitors in RA patients who discontinued JAK inhibitor therapy.
Amstad A; Papagiannoulis E; Scherer A; Rubbert-Roth A; Finckh A; Mueller R; Dudler J; Möller B; Villiger PM; Schulz MMP; Kyburz D
Rheumatology (Oxford); 2022 Dec; 62(1):89-97. PubMed ID: 35579338
[TBL] [Abstract][Full Text] [Related]
16. Comparative effectiveness of tocilizumab versus TNF inhibitors as monotherapy or in combination with conventional synthetic disease-modifying antirheumatic drugs in patients with rheumatoid arthritis after the use of at least one biologic disease-modifying antirheumatic drug: analyses from the pan-European TOCERRA register collaboration.
Lauper K; Nordström DC; Pavelka K; Hernández MV; Kvien TK; Kristianslund EK; Santos MJ; Rotar Ž; Iannone F; Codreanu C; Lukina G; Gale SL; Sarsour K; Luder Y; Courvoisier DS; Gabay C
Ann Rheum Dis; 2018 Sep; 77(9):1276-1282. PubMed ID: 29730637
[TBL] [Abstract][Full Text] [Related]
17. Malignant Neoplasms in Patients With Rheumatoid Arthritis Treated With Tumor Necrosis Factor Inhibitors, Tocilizumab, Abatacept, or Rituximab in Clinical Practice: A Nationwide Cohort Study From Sweden.
Wadström H; Frisell T; Askling J;
JAMA Intern Med; 2017 Nov; 177(11):1605-1612. PubMed ID: 28975211
[TBL] [Abstract][Full Text] [Related]
18. Efficacy of pharmacological treatment in rheumatoid arthritis: a systematic literature research informing the 2019 update of the EULAR recommendations for management of rheumatoid arthritis.
Kerschbaumer A; Sepriano A; Smolen JS; van der Heijde D; Dougados M; van Vollenhoven R; McInnes IB; Bijlsma JWJ; Burmester GR; de Wit M; Falzon L; Landewé R
Ann Rheum Dis; 2020 Jun; 79(6):744-759. PubMed ID: 32033937
[TBL] [Abstract][Full Text] [Related]
19. Drug retention of sarilumab, baricitinib, and tofacitinib in patients with rheumatoid arthritis: the ANSWER cohort study.
Ebina K; Hirano T; Maeda Y; Yamamoto W; Hashimoto M; Murata K; Onishi A; Jinno S; Hara R; Son Y; Amuro H; Takeuchi T; Yoshikawa A; Katayama M; Yamamoto K; Hirao M; Okita Y; Kumanogoh A; Nakata K
Clin Rheumatol; 2021 Jul; 40(7):2673-2680. PubMed ID: 33515115
[TBL] [Abstract][Full Text] [Related]
20. Persistence of Janus-kinase (JAK) inhibitors in rheumatoid arthritis: Australia wide study.
Scheepers L; Yang Y; Chen YL; Jones G
Semin Arthritis Rheum; 2024 Feb; 64():152314. PubMed ID: 38029717
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
